Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis

International Journal of Cardiology

Volumn 205, Issue , 2016, Pages 65-71

  Xie, Wuxiang ^a   Zheng, Fanfan ^b   Song, Xiaoyu ^c   Zhong, Baoliang ^d   Yan, Li ^e  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF AUTOMATION   (China)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Heart failure and reduced ejection fraction; Left ventricular dysfunction; Network meta analysis; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; PLACEBO; RENIN INHIBITOR;

AGE DISTRIBUTION; ARTICLE; BAYES THEOREM; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SEX DIFFERENCE; SYSTEMATIC REVIEW; DRUG EFFECTS; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; PHYSIOLOGY; PROCEDURES; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HEART FAILURE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84955465558     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.12.010     Document Type: Article

References (46)

1. C. Berry, D.R. Murdoch, and J.J. McMurray Economics of chronic heart failure Eur. J. Heart Fail. 3 2001 283 291
2. C.W. Yancy, M. Jessup, B. Bozkurt, and et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines J. Am. Coll. Cardiol. 62 2013 e147 e239
3. A.S. Go, D. Mozaffarian, V.L. Roger, and et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association Circulation 129 2014 e28 e292
4. S.F. Jencks, M.V. Williams, and E.A. Coleman Rehospitalizations among patients in the medicare fee-for-service program N. Engl. J. Med. 360 2009 1418 1428
5. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group N. Engl. J. Med. 316 1987 1429 1435
6. J.J. McMurray, S. Adamopoulos, S.D. Anker, and et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC Eur. Heart J. 33 2012 1787 1847
7. M. Gheorghiade, M. Bohm, S.J. Greene, and et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial JAMA 309 2013 1125 1135
8. J.J. McMurray, M. Packer, A.S. Desai, and et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure N. Engl. J. Med. 371 2014 993 1004
9. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement PLoS Med. 6 2009 e1000097
10. F. Song, T. Xiong, S. Parekh-Bhurke, and et al. Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study BMJ 343 2011 d4909
11. F. Edelmann, R. Wachter, A.G. Schmidt, and et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial JAMA 309 2013 781 791
12. S. Yusuf, M.A. Pfeffer, K. Swedberg, and et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial Lancet 362 2003 777 781
13. B.M. Massie, P.E. Carson, J.J. McMurray, and et al. Irbesartan in patients with heart failure and preserved ejection fraction N. Engl. J. Med. 359 2008 2456 2467
14. S.D. Solomon, M. Zile, B. Pieske, and et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial Lancet 380 2012 1387 1395
15. J.G. Cleland, M. Tendera, J. Adamus, and et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study Eur. Heart J. 27 2006 2338 2345
16. B. Pitt, M.A. Pfeffer, S.F. Assmann, and et al. Spironolactone for heart failure with preserved ejection fraction N. Engl. J. Med. 370 2014 1383 1392
17. J.P. Higgins, and S. Green Chapter 8: assessing risk of bias in included studies J.P. Higgins, D.G. Altman, J.A. Sterne, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 2011 John Wiley & Sons Chichester 8.1 8.53
18. G. Salanti, A.E. Ades, and J.P. Ioannidis Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial J. Clin. Epidemiol. 64 2011 163 171
19. The Biostatistics Unit, Medical Research Council, Cambridge Institute of Public Health. WinBUGS 1.4.3. (Available at: http://www.mrc-bsu.cam.ac.uk/software/bugs. Accessed February 11, 2015).
20. Salanti G, Mavridis D, Nikolakopoulou A, Gianiatsi M. Multiple-treatments meta-analysis of a network of interventions. (Available at: http://www.mtm.uoi.gr/index.php/how-to-do-an-mtm. Accessed February 11, 2015).
21. R.S. McKelvie, S. Yusuf, D. Pericak, and et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD pilot study investigators Circulation 100 1999 1056 1064
22. M.A. Pfeffer, J.J. McMurray, E.J. Velazquez, and et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N. Engl. J. Med. 349 2003 1893 1906
23. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators Lancet 342 1993 821 828
24. A. Matsumori Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure Eur. J. Heart Fail. 5 2003 669 677
25. A. Boccanelli, G.F. Mureddu, G. Cacciatore, and et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results Eur. J. Heart Fail. 11 2009 68 76
26. J.J. McMurray, J. Ostergren, K. Swedberg, and et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial Lancet 362 2003 767 771
27. C.B. Granger, J.J. McMurray, S. Yusuf, and et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial Lancet 362 2003 772 776
28. B. Pitt, R. Segal, F.A. Martinez, and et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) Lancet 349 1997 747 752
29. B. Pitt, P.A. Poole-Wilson, R. Segal, and et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II Lancet 355 2000 1582 1587
30. F. Zannad, J.J. McMurray, H. Krum, and et al. Eplerenone in patients with systolic heart failure and mild symptoms N. Engl. J. Med. 364 2011 11 21
31. B. Pitt, W. Remme, F. Zannad, and et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N. Engl. J. Med. 348 2003 1309 1321
32. K. Dickstein, and J. Kjekshus Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan Lancet 360 2002 752 760
33. B. Pitt, F. Zannad, W.J. Remme, and et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators N. Engl. J. Med. 341 1999 709 717
34. M.A. Pfeffer, E. Braunwald, L.A. Moye, and et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators N. Engl. J. Med. 327 1992 669 677
35. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors N. Engl. J. Med. 327 1992 685 691
36. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators N. Engl. J. Med. 325 1991 293 302
37. L. Kober, C. Torp-Pedersen, J.E. Carlsen, and et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group N. Engl. J. Med. 333 1995 1670 1676
38. J.N. Cohn, and G. Tognoni A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N. Engl. J. Med. 345 2001 1667 1675
39. J. McMurray, M. Packer, A. Desai, and et al. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure Eur. Heart J. 36 2015 434 439
40. G.W. Moe, J.A. Ezekowitz, E. O'Meara, and et al. The 2014 Canadian Cardiovascular Society Heart Failure Management guidelines focus update: anemia, biomarkers, and recent therapeutic trial implications Can. J. Cardiol. 31 2015 3 16
41. J.J. McMurray, B. Pitt, R. Latini, and et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure Circ. Heart Fail. 1 2008 17 24
42. H. Krum, B. Massie, W.T. Abraham, and et al. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to minimize OutcomeS in patients with HEart failuRE (ATMOSPHERE) study Eur. J. Heart Fail. 13 2011 107 114
43. A. Coats, and L. Shewan The management of heart failure with preserved ejection fraction (HFpEF) Int. Cardiovasc. Forum J. 1 2014 108 112
44. J. Sanderson Comments on "the management of Heart Failure with preserved ejection fraction" Int. Cardiovasc. Forum J. 1 2014 166
45. P. Juni, F. Holenstein, J. Sterne, and et al. Direction and impact of language bias in meta-analyses of controlled trials: empirical study Int. J. Epidemiol. 31 2002 115 123
46. H. Krum, B. Massie, W.T. Abraham, and et al. What contributions do languages other than English make on the results of meta-analyses? J. Clin. Epidemiol. 53 2000 964 972